Home › Multiple Sclerosis › Massachusetts › Brockton
Multiple Sclerosis clinical trials in Brockton, MA
4 studies for Multiple Sclerosis are looking for participants at sites in and around Brockton (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
RecruitingObservational study
- TG Therapeutics Investigational Trial Site, Norfolk · 16 mi away
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
RecruitingPhase 2
- Neurology Center of New England, Foxborough · 12 mi away
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
RecruitingPhase 3
- Neuro Institute of New England P C, Foxborough · 12 mi away
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
RecruitingObservational study
- Neurology Center of New England P.C., Foxborough · 12 mi away
About Multiple Sclerosis
Multiple sclerosis (MS) slows down or blocks messages between the brain and body. MS can be mild or severe. Learn about MS symptoms and treatment.
More about Multiple Sclerosis on MedlinePlus
Multiple Sclerosis trials in other cities
- New York City, NY17 studies
- Chicago, IL15 studies
- Boston, MA14 studies
- Washington, DC13 studies
- Cleveland, OH9 studies
- St. Louis, MO8 studies
- Kansas City, KS8 studies
- Birmingham, AL8 studies
- San Francisco, CA8 studies
- Seattle, WA7 studies
- Columbus, OH7 studies
- Baltimore, MD7 studies
Other studies in Brockton
- Breast Cancer5 studies
- Alzheimer's Disease4 studies
- Prostate Cancer4 studies
- Colon Cancer3 studies
- Non-Muscle Invasive Bladder Cancer3 studies
- Myasthenia Gravis3 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.